Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Setanaxib - GenKyoTex

Drug Profile

Setanaxib - GenKyoTex

Alternative Names: GKT 831; GKT-137831

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenKyoTex
  • Developer Calliditas Therapeutics; GenKyoTex; University of California, Davis; University of California, San Diego
  • Class Amines; Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Chlorinated hydrocarbons; Eye disorder therapies; Ketones; Osteoporosis therapies; Pyrazoles; Pyridines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma; Primary biliary cirrhosis; Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Primary biliary cirrhosis
  • Phase II Diabetic nephropathies; Hereditary nephritis; Idiopathic pulmonary fibrosis; Squamous cell cancer
  • No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
  • Discontinued Atherosclerosis; Bone disorders; Eye disorders

Most Recent Events

  • 30 Nov 2023 Phase-II clinical trials in Hereditary nephritis (PO)
  • 05 Oct 2023 The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the company's application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome
  • 29 Sep 2023 Calliditas Therapeutics plans phase-II trial for Hereditary nephritis in the fourth quarter of 2023 (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top